S. Arebee A. CRISPR Gene-Editing Therapies for Sickle Cell Disease and Beta- Thalassemia: Clinical Outcomes, Risks and Safety Profiles. A Systematic Review. ljmas [Internet]. 2025 Dec. 31 [cited 2026 Jan. 23];3(4):102-8. Available from: https://ljmas.com/index.php/journal/article/view/254